IRIS
POLONI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.522
EU - Europa 4.358
AS - Asia 1.740
SA - Sud America 369
AF - Africa 143
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 6
Totale 13.157
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.507
IT - Italia 936
UA - Ucraina 775
RU - Federazione Russa 544
SG - Singapore 496
IE - Irlanda 473
SE - Svezia 412
DE - Germania 384
CN - Cina 342
BR - Brasile 340
HK - Hong Kong 321
TR - Turchia 305
DK - Danimarca 288
FI - Finlandia 205
KR - Corea 158
GB - Regno Unito 133
FR - Francia 109
CI - Costa d'Avorio 77
IN - India 58
MA - Marocco 48
AT - Austria 25
BE - Belgio 22
EU - Europa 19
JP - Giappone 14
NL - Olanda 13
PL - Polonia 12
UZ - Uzbekistan 8
CA - Canada 7
AR - Argentina 6
TN - Tunisia 6
AU - Australia 5
CH - Svizzera 5
CO - Colombia 5
EC - Ecuador 5
IQ - Iraq 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
ES - Italia 4
MX - Messico 4
PE - Perù 4
BD - Bangladesh 3
BG - Bulgaria 3
BZ - Belize 3
IR - Iran 3
PY - Paraguay 3
RO - Romania 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
DZ - Algeria 2
IL - Israele 2
KE - Kenya 2
MT - Malta 2
NP - Nepal 2
PH - Filippine 2
PK - Pakistan 2
PS - Palestinian Territory 2
PT - Portogallo 2
UY - Uruguay 2
VN - Vietnam 2
AL - Albania 1
BH - Bahrain 1
BJ - Benin 1
CG - Congo 1
CL - Cile 1
ET - Etiopia 1
HN - Honduras 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
OM - Oman 1
TM - Turkmenistan 1
Totale 13.157
Salva come PNG Salva come JPEG
Città #
Jacksonville 820
Chandler 752
Fairfield 619
Dublin 473
Boardman 458
Ashburn 375
Des Moines 337
Wilmington 325
Hong Kong 320
New York 243
Singapore 239
Houston 232
Seattle 231
Woodbridge 209
Lawrence 182
Princeton 182
San Mateo 176
Cambridge 147
Ann Arbor 129
Centro 112
Moscow 110
San Diego 78
Abidjan 77
Redmond 74
The Dalles 68
Turin 64
Beijing 62
Ancona 56
Milan 51
Helsinki 50
Rome 47
Marche 46
Pune 39
Guangzhou 35
Shanghai 34
Porto 33
Norwalk 27
Pianella 27
London 26
Los Angeles 26
São Paulo 22
Washington 22
Nuremberg 21
Brussels 19
Naples 17
Vienna 15
Dallas 14
Falconara Marittima 14
Wuhan 14
Hangzhou 12
Wuxi 12
Rio de Janeiro 11
San Benedetto del Tronto 11
Kilburn 9
Tolentino 9
Acerra 8
Brasília 8
Istanbul 8
Philadelphia 8
Prescot 8
Shenzhen 8
Tashkent 8
Venice 8
Dunstable 7
Florence 7
Pavia 7
Andria 6
Belo Horizonte 6
Fayetteville 6
Hyderabad 6
Southwark 6
Curitiba 5
Jiaxing 5
Jinhua 5
Leeds 5
Manaus 5
Osimo 5
Santo André 5
Torino 5
Vila Velha 5
Auburn Hills 4
Baku 4
Castelnuovo Rangone 4
Chiaravalle 4
Chiswick 4
Falls Church 4
Guarulhos 4
Heze 4
Hounslow 4
Izmir 4
Jinan 4
Jundiaí 4
Mistretta 4
Mumbai 4
New Bedfont 4
Perugia 4
Pistoia 4
Porto Alegre 4
Praia Grande 4
Tunis 4
Totale 8.053
Salva come PNG Salva come JPEG
Nome #
Algoritmi diagnostico-terapeutici in Ematologia 266
Human white adipocytes convert into “rainbow” adipocytes in vitro 205
Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome? 158
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. 144
Human de-differentiated adipocytes show similar properties to bone marrow derived mesenchymal stem cells 143
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment 141
Conditioning regimen with beam plus amifostine for outpatient autologous stem cell tansplantation: feasibility and outcome in 97 lymphoma patients. 130
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 127
Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. 116
Glial-like differentiation potential of human mature adipocytes 116
Human bone marrow adipocytes maintain the survival and differentiation of hematopoietic stem cells 111
Azacitidine Treatment in High Risk Myelodysplastic Patients in Complete Haematological Remission Reverts Mesenchymal Stem Cells to a Normal Phenotype 111
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 110
High predictive value of the revised international prognostic scoring system (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry 108
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease 107
Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. 106
A real life survey on erytropoietin alpha treatment in a cohort of 1049 low risk MDS patients: an italian MDS registry study 105
Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes. 103
The exosomal surface phenotype and inflamma-miR cargo correlate with MDS diagnosis 103
Apoptotic mechanism activated by blue light and cisplatinum in cutaneous squamous cell carcinoma cells 103
Efficacy and feasibility of high-dose cytarabine plus idarubicin and amifostine as induction schedule: a prospective observational study of 100 AML elderly patients 102
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. 102
Plasticity of human dedifferentiated adipocytes toward endothelial cells 100
Biosafety evidence for human dedifferentiated adipocytes 99
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 99
The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib 99
A Combination of Lenalidomide and Rituximab (ReRi) As Salvage Therapy in Elderly Patients Affected By Diffuse Large B Cells (DLBCL) Lymphoma Relapsed and Refractory 97
Adipocytes properties and crosstalk with immune system in obesity-related inflammation. 97
Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin 96
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study 95
Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate 92
Molecular and functional characterization of human bone marrow adipocytes 92
Hematologic reconstitution after PBPC autotransplantation:comparison between programmed-rate freezing and uncontrolled freezing at –80° 90
Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. 90
Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis 89
Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS) 88
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study 87
LA POSITIVITÀ DEL WT1 POST-INDUZIONE È UN IMPORTANTE FATTORE PROGNOSTICO PREDITTIVO DI RECIDIVA PRECOCE IN UNA CASISTICA DI 80 PAZIENTI AFFETTI DA LEUCEMIA ACUTA MIELOIDE 87
The Time Has Come for Targeted Therapies for AML: Lights and Shadows 87
Bone marrow adipocytes support haematopoietic stem cell survival 86
Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. 83
Preventive Effects of Cardotoxicities By Liposomal Anthracyclines non Pegilated in 95 Perspective Patients Affected By Lymphoma and Monitored By Biomarkers and Ecocardiography 83
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 83
Gemtuzumab-Ozogamicin as Post-Consolidation Therapy In Elderly Patients with Acute Myeloid Leukemia: a Pilot Study 83
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 83
History and scientific production of clinica medica and clinica ematologica in ancona 82
Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow 81
Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation 81
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. 81
LATE EFFECTS IN Hodgkin's POPULATION Treated BETWEEN 1980-2005 IN A SINGLE INSTITUTION 81
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 81
Human Mesenchymal Stem Cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion 81
CHANGES IN RPS14 EXPRESSION LEVELS DURING LENALIDOMIDE TREATMENT IN LOW- AND INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITH CHROMOSOME 5Q DELETION 80
Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes 80
Long duration of response to azacitidine in MDS. Multicenter retrospective study of 36 patients 79
DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype 79
Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes 79
Targeting the immune system in MDS and MPN: Understanding the immunome and response to immunotherapy - Part 2 78
Cytokine expression profile of selected cell populations from patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation wih reduced conditioning. 77
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 76
Emopoiesi normale e mielodisplastica 76
Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. 76
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 76
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. 75
Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. 75
QUALITY OF LIFE ASSESSMENT IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME 74
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study 74
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems 72
VERY LOW TOXICITY AND GOOD QUALITY OF LIFE IN 48 ELDERLY PATIENTS AUTOTRANSPLANTED FOR HEMATOLOGICAL MALIGNANCIES: A SINGLE CENTER EXPERIENCE 71
Prognostic factors of response to erytropoiesis stimulating agents (ESA) Treatment in non RBC transfusion dependent lower risk MDS. Preliminary results of a french and italian study (on behalf of the GFM and FISM) 70
TREATMENT WITH AZACITIDINE REVERSES MESENCHYMAL STEM CELLS DERIVED FROM HIGH RISK MYELODYSPLASTIC PATIENTS TO A NORMAL PHENOTYPE 70
Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. 69
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome 69
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? 69
Identification of different adypocytes populations within human marrow microenvironment 69
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 69
Hematologic reconstitution after PBPC autotransplantation: comparison between programmed-rate freezing and uncontrolled-rate freezing at -80 degrees C 68
Predictive value of post-induction and post-consolidation MRD: a comparison of multiparameter flow cytometry and WT1 RT-PCR techniques in 75 acute myeloid leukemia (AML) patients 68
Bone Marrow "Yellow" and "Red" Adipocytes: Good or Bad Cells? 68
CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE 67
OVEREXPRESSION OF CDKN2B IS ASSOCIATED WITH REDUCED PROLIFERATIVE POTENTIAL IN MESENCHYMAL STEM CELL FROM HIGH-RISK MYELODYSPLASTIC SYNDROME 67
LENALIDOMIDE FOR THE TREATMENT OF LOW- AND INT-1-RISK MDS WITH DEL(5Q): EFFICACY AND QUALITY OF LIFE STUDY 66
AMIFOSTINE CAN REDUCE MUCOSAL DAMAGE AFTER HIGH-DOSE MELPHALANCONDITIONING FOR PERIPHERAL BLOOD PROGENITOR CELL AUTOTRANSPLANT: A RETROSPECTIVE STUDY. EFFECT OF AMIFOSTINE ON MUCOSITIS DURING AUTOLOGOUS PBPC TRANSPLANTATION 66
Assessment and monitoring of CMV infection in patients receiving a reduced-intensity conditioning allogeneic transplant: comparison of antigenaemia assay with quantitative PCR 66
Post-transplant events Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders 66
P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome 66
GENE EXPRESSION CHANGES IN BONE MARROW OF MDS PATIENTS WITH DEL(5Q) DURING LENALIDOMIDE TREATMENT 65
Mesenchymal stem cells of myelodysplastic syndromes show impaired hematopoietic support function and global DNA hypermethylation status 65
Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q) 65
Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society 65
Strategie generali di trattamento 64
COMPARISON OF CD34+ BONE MARROW CELLS PURIFIED BY IMMUNOMAGNETIC AND IMMUNOADSORPTION CELL SEPARATION TECHNIQUES 64
Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. 64
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 64
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell trasplantation 63
EX VIVO PHARMACOLOGICAL PURGING OF LEUKAPHERESIS COLLECTIONS WITH NITROGEN MUSTARD: AMIFOSTINE PRETREATMENT IMPROVES BOTH EARLY AND LATE PERIPHERAL BLOOD PROGENITOR CELL RECOVERY 63
P112 Gene expression patterns in MDS with del5q before and during lenalidomide treatment 63
PBSC collection after high dose chemotherapy followed by G-CSF in patients with malignancies: analysis of results regarding factors affecting the yield of hemopoietic progenitors. 62
A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study 61
TELOMERE MAINTENANCE IN MYELOID MALIGNANCIES 60
Totale 8.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020287 0 0 0 0 0 0 0 0 0 0 72 215
2020/20212.558 100 235 344 48 354 217 266 117 313 177 263 124
2021/20221.467 72 351 26 90 10 80 68 111 91 131 136 301
2022/20232.479 225 241 208 188 155 516 2 120 584 10 184 46
2023/20241.626 228 49 87 233 254 371 42 35 5 56 33 233
2024/20252.696 357 318 141 61 131 101 305 101 859 262 60 0
Totale 13.626